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Objectives. This study estimated the prevalence of medication treatment for attention deficit–
hyperactivity disorder (ADHD) among elementary school children in a North Carolina county.
Methods. Parents of 7333 children in grades 1 through 5 in 17 public elementary schools were
asked whether their child had ever been given a diagnosis of ADHD by a psychologist or physician and
whether their child was currently taking medication to treat ADHD. Parents of 6099 children (83%) re-
sponded.
Results. By parental report, 607 children (10%) had been given an ADHD diagnosis and 434 (7%)
were receiving ADHD medication treatment. Seventy-one % of the diagnosed children were receiving med-
ication. Treatment rates varied by sex, race/ethnicity, and grade.
Conclusions. If treatment patterns observed in this study are representative, the public health im-
pact of ADHD may be underestimated. (Am J Public Health. 2002;92:231–234)
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for the Epidemiology of Child and Adolescent
Mental Disorders (MECA) study, a large epi-
demiologic survey of 4 US communities, re-
ported that about 2% of the children in its
sample were receiving ADHD medication
treatment.8 However, the children in the
MECA study were aged 9 to 17 years. It is
difficult to compare these data with those
from samples of younger children, because
medication rates tend to decline sharply
among teenagers.9
In this article, we use parent reports to esti-
mate the prevalence of medication treatment
for ADHD among public elementary school
children in grades 1 through 5 in a North
Carolina county and to examine how preva-
lence varies by grade, sex, and race/ethnicity.
METHODS
Study Population
We defined our sample as all children en-
rolled in grades 1 through 5 in Johnston
County’s 17 public elementary schools. We
excluded Johnston County children of ele-
mentary school age who were attending pri-
vate schools (n=75), receiving home school-
ing (n=140), or attending middle schools
(n=268) because of concern that their learn-
ing environments might be different from
those in public elementary schools. We ex-
cluded children with severe developmental
disabilities placed in self-contained classrooms
(n=146). We also excluded children attend-
ing regular classes with special education des-
ignations for autism, mental handicap (IQ<70),
or severe health disabilities (such as traumatic
head injury or childhood cancer) (n=114).
Children with learning disabilities or behavior
problems were included in the sample regard-
less of classroom placement. A total of 7333
children were eligible.
Assessment
We surveyed parents from 8 schools dur-
ing 1997 to 1998 and from the remaining 9
schools during 1998 to 1999. Parents with
more than 1 child in elementary school re-
ceived a questionnaire for each child. We
asked parents 2 questions: (1) “Has a doctor
or psychologist ever told you that your child
has attention-deficit disorder (ADD), attention
deficit–hyperactivity disorder (ADHD), or hy-
peractivity?” and (2) “Is your child currently
taking any medicine prescribed by a doctor to
help with symptoms of ADHD (for example,
inattention or hyperactivity) or to help the
child’s mood or behavior?” If parents re-
Population-based data on the prevalence of
medication treatment for attention deficit–
hyperactivity disorder (ADHD) are limited.
Data on national prescribing trends are
available and have been used to estimate
the proportion of office visits in which a
stimulant medication is prescribed.1–3 How-
ever, these data cannot be used to estimate
the proportion of children with ADHD who
are being treated with stimulant medication,
because in any year, each treated child typi-
cally has multiple office visits and receives
many prescriptions.4
Some studies have estimated the preva-
lence of ADHD medication treatment on the
basis of school records. In 1987, Safer and
Krager5 estimated that 6% of the elementary
school children in Baltimore, Md, received
medication treatment for ADHD. LeFever et
al.6 estimated that between 8% and 10% of
second- through fifth-grade students in 2 Vir-
ginia school districts were receiving stimulant
medication at school in 1995. In the Virginia
study, treatment rates were particularly high
among White boys: 17% took stimulant med-
ication at school.6 In 2000, a survey con-
ducted among school nurses in Maryland re-
ported that 3.7% of all public elementary
school children took ADHD medication at
school.7
School-based surveys have an important
limitation: they exclude children who take
their medication only at home. Many parents
choose to give medication at home by admin-
istering slow-release forms of stimulant med-
ications. The authors of the Maryland school
nurse study acknowledged this problem; they
estimated that they missed about 20% of the
children who were being treated for ADHD
in their study population.7
Few population-based parent surveys of
ADHD medication treatment rates among
schoolchildren have been done. The Methods
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TABLE 1—Prevalence of Parent-Reported Attention Deficit–Hyperactivity Disorder (ADHD) 
Diagnosis and Parent-Reported Current Use of ADHD Medication
Children Previously Diagnosed With ADHD Children Currently Taking ADHD Medication
Adjusted Adjusted
Children in Sample
Prevalence, Prevalence Prevalence, Prevalence
Grouping N % of Total N % 95% CI Ratioa 95% CI N % 95% CI Ratioa 95% CI
Total sample 6099 100.0 607 10.0 (9.2, 10.7) 434 7.1 (6.5, 7.8)
Study year
1 3012 49.4 307 10.1 (9.2, 11.3) 205 6.8 (6.0, 7.8)
2 3087 50.6 300 9.7 (8.7, 10.8) 229 7.4 (6.5, 8.4)
Sex
Girls 2951 48.4 140 4.7 (4.0, 5.6) 1.0 92 3.1 (2.5, 3.8) 1.0
Boys 3148 51.6 467 14.8 (13.6, 16.1) 3.1 (2.6, 3.7) 342 10.9 (9.8, 12.0) 3.5 (2.8, 4.3)
Race/ethnicity
White 4437 72.7 479 10.8 (9.9, 11.7) 1.0 364 8.2 (7.4, 9.1) 1.0
Black 1208 19.8 110 9.1 (7.6, 10.9) 0.9 (0.7, 1.1) 62 5.1 (4.0, 6.5) 0.7 (0.5, 0.8)
Hispanic 376 6.2 15 4.0 (2.4, 6.6) 0.4 (0.2, 0.6) 8 2.1 (1.1, 4.2) 0.3 (0.1, 0.5)
Other 78 1.3 3 3.9 (1.3, 11.7) 0.4 (0.1, 1.2) 0 0.0 . . . 0.0 . . .
Grade
1 1425 23.4 93 6.5 (5.6, 7.9) 1.0 62 4.4 (3.4, 5.5) 1.0
2 1367 22.4 112 8.2 (6.9, 9.8) 1.2 (1.0, 1.6) 81 5.9 (4.8, 7.3) 1.3 (1.0, 1.8)
3 1222 20.0 131 10.7 (9.1, 12.6) 1.6 (1.2, 2.0) 97 7.9 (6.6, 9.6) 1.7 (1.3, 2.4)
4 1140 18.7 149 13.1 (11.3, 15.2) 2.0 (1.6, 2.5) 107 9.4 (7.8, 11.2) 2.1 (1.6, 2.8)
5 945 15.5 122 12.9 (10.9, 15.2) 1.9 (1.5, 2.5) 87 9.2 (7.5, 11.2) 2.0 (1.5, 2.8)
Note. CI = confidence interval.
aPrevalence ratios were adjusted for sex, grade, and race/ethnicity.
ported that their child was taking medication,
we also asked them to name the medicine.
We categorized children as taking ADHD
medication if their parents answered yes to
both questions.
Analysis
To calculate confidence intervals (CIs) for
prevalence and prevalence ratios and to ad-
just for covariates, we fitted generalized linear
models with a logarithmic link function and a
binomial error distribution.10,11 The calcula-
tions were done with the GENMOD proce-
dure in SAS software (SAS Institute Inc, Cary,
NC). Prevalence ratios were adjusted for sex,
race/ethnicity, and grade.
RESULTS
Parents of 6099 children (83%) answered
both questions about their child’s history of
diagnosis and current medication treatment.
This report is based on these 6099 children.
According to their parents, 607 children
(10% of the sample) had ever been given an
ADHD diagnosis. Prevalence estimates for
various subgroups and prevalence ratios ad-
justed for sex, race/ethnicity, and grade ap-
pear in Table 1. Prevalence of ADHD diagno-
sis was similar for both years of the study.
About 15% of the boys and 5% of the girls
had been given an ADHD diagnosis (adjusted
prevalence ratio=3.1, 95% CI=2.6, 3.7, P<
.001). African American children were only
slightly less likely than White children to
have been diagnosed with ADHD (adjusted
prevalence ratio=0.9, 95% CI=0.7, 1.1, P=
.19). Hispanic children were much less likely
to have been diagnosed with ADHD (ad-
justed prevalence ratio=0.4, 95% CI=0.2,
0.6, P<.001). The proportion of children
with a history of ADHD diagnosis increased
with age, from 6.5% in grade 1 to a high of
about 13% in grades 4 and 5.
By parental report, 434 children (7.1%,
95% CI=6.5, 7.8) were currently receiving
medication to treat ADHD (Table 1). Medica-
tion treatment rates were similar during both
years of the study. About 11% of the boys in
the sample were taking ADHD medication,
compared with about 3% of the girls. ADHD
medication treatment also varied by race/eth-
nicity. About 8% of the White children were
currently receiving medication treatment,
compared with 5% of the African American
children and 2% of the Hispanic children. In
comparison with White children, the preva-
lence ratio of ADHD medication treatment
was 0.7 (95% CI=0.5, 0.8, P=.001) among
African American children and 0.3 (95%
CI=0.1, 0.5, P<.001) among Hispanic chil-
dren after adjustment for grade and sex. Med-
ication treatment rates tended to increase
with grade: more than 9% of the children in
both the fourth and the fifth grades were tak-
ing medication to treat ADHD.
Of the children who had ever been given
an ADHD diagnosis, 71% were currently re-
ceiving medication treatment. Even though 3
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Note. Vertical axis represents unadjusted proportion of children taking stimulant medications (methylphenidate,
amphetamines, or pemoline). Standard error bars are provided for each subgroup.
FIGURE 1—Prevalence of attention deficit–hyperactivity disorder stimulant medication
treatment, by grade, race/ethnicity, and sex.
times as many boys as girls were taking
ADHD medication, the proportions of diag-
nosed children of each sex receiving treatment
barely differed: 73% of the boys and 66% of
the girls (adjusted prevalence ratio=1.1, 95%
CI=1.0, 1.3, P=.05). Racial/ethnic differ-
ences in the proportion treated were more
pronounced: 76% of the ADHD-diagnosed
White children were taking medication, com-
pared with 56% of the African American and
53% of the Hispanic children. The adjusted
prevalence ratios relative to Whites were 0.7
(95% CI=0.6, 0.9, P<.001) and 0.7 (95%
CI=0.4, 1.1, P=.12), respectively.
Of the 434 children receiving treatment,
402 (93%) were taking a stimulant; 9.7% of
those taking a stimulant were taking at least 1
other medication. Medication type was miss-
ing for 2 children. Of the 30 children taking
other medications, 16 were taking a centrally
acting adrenergic receptor agent (clonidine or
guanfacine) and 14 were taking either an an-
tidepressant or a mood stabilizer.
Treatment rates with stimulant medication
were particularly high for White boys (Figure
1). More than 15% of the White boys in the
fourth and fifth grades (123 of 800) were
currently taking stimulant medication. In
fourth-grade students, the proportion of Afri-
can American boys taking stimulant medica-
tion (10 of 111, 9%) was about 60% that of
White boys (63 of 426, 15%). The rate of
stimulant treatment for African American
boys was lower in the fifth grade. This sharp
decrease was probably a methodologic arti-
fact; the 2 schools with the highest rates of
stimulant treatment for African American
boys lacked a fifth grade. Children from these
schools attended middle school in fifth grade
and therefore were not included in the sam-
ple. Stimulant medication treatment rates
were higher among White girls than among
African American girls in each grade, but the
racial/ethnic disparity was less pronounced
among girls than among boys.
DISCUSSION
The prevalence of parent-reported ADHD
medication treatment reported here (7%) is
similar to that reported in 2 school-based stud-
ies.5,6 Heretofore, treatment rates were viewed
as abnormally high if they exceeded the 3% to
5% prevalence estimate for ADHD cited in
the Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition (DSM-IV).12 ADHD
prevalence estimates vary widely, however, de-
pending on the methodology used.13
Our study was conducted in only 1 county,
so the generalizability of our results is not
clear. It is difficult to gauge to what extent
treatment patterns in Johnston County pertain
to other parts of North Carolina or the United
States. Johnston County has a racial/ethnic
and educational profile similar to that of
North Carolina as a whole. In addition, the
authors of the Great Smoky Mountain study,
a study of children’s mental health in 11 west-
ern North Carolina counties, reported that
7.3% of the children in their sample were
being treated with stimulant medication.14
However, that study oversampled children
with psychiatric disorders and Native Ameri-
can children, so those data are not directly
comparable with ours. Additional population-
based studies of the prevalence of ADHD
medication treatment are needed.
Our data are consistent with other observa-
tions that suggest that the prevalence of med-
ication treatment for ADHD is higher among
boys than among girls15,16 and higher among
Whites than among African Americans.6,15–17
Our data showed only a small difference in
history of diagnosis between Whites and Afri-
can Americans but a substantial difference in
medication treatment rates between the 2
groups. Hispanic children were the least likely
to have been given an ADHD diagnosis or to
be receiving medication treatment for ADHD.
Our data on Hispanics should be interpreted
cautiously because of small numbers. Never-
theless, the Maryland school nurse study also
reported low treatment rates among Hispanic
children.7
Demographic variation in the prevalence of
medication treatment may be important. Dif-
ferences in treatment rates between boys and
girls may reflect sex differences in the preva-
lence of ADHD, but it also may reflect refer-
ral bias.18,19 Despite the sex difference in treat-
ment rates, it was reassuring to see that once
diagnosed with ADHD, boys and girls re-
ceived medication in similar proportions. In
contrast, significantly smaller proportions of
African American and Hispanic children than
of White children with ADHD were receiving
medication treatment. We are not sure why.
Compared with White children, Hispanic and
African American children face many barriers
to care, including less access to medical pro-
viders, less health insurance coverage, and
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less ability to pay for medication.15 Cultural
differences also may influence parents’ or
children’s acceptance of using medication to
treat ADHD. In addition, difficulties in speak-
ing English may mask inattention symptoms
among Hispanic children.
Both history of diagnosis of ADHD and
current medication treatment were based on
parent report and not confirmed with medical
or pharmacy records. The nomenclature and
diagnostic criteria for ADHD have been re-
vised several times over the past 10 years,20
and many primary care physicians do not use
DSM-IV when diagnosing attentional disor-
ders.21 Thus, parent-reported history of a di-
agnosis of ADHD is likely to be a poor surro-
gate for the true DSM-IV prevalence of
ADHD in a study population. The data pre-
sented here can estimate the prevalence of
medication treatment but do not address
whether ADHD is under- or overdiagnosed or
under- or overtreated in our population.
Obtaining information on children’s medica-
tion use from parents instead of from school
records avoids missing children who take med-
ication only at home. However, response bias
is a potentially important problem for parent-
based surveys. Our study had a relatively high
response rate (83%), but we had little informa-
tion from which to assess selection bias. Sev-
eral scenarios are plausible. Some parents of
children with ADHD may have chosen not to
participate because of concerns about confi-
dentiality, whereas others may have been mo-
tivated to participate out of a desire to increase
public understanding of the disorder.
We may have misclassified some children
as taking ADHD medication if they were tak-
ing a medication prescribed for a comorbid
condition such as anxiety or depression. We
believe, however, that any resulting bias was
probably small, because only 7% of the chil-
dren we classified as taking ADHD medica-
tion were not taking a stimulant.
Few community-based studies of the preva-
lence of ADHD and the prevalence of ADHD
medication treatment exist. Since 1997, the Na-
tional Health Interview Survey has asked about
history of diagnosis of “attention deficit disor-
der.” This phrasing is potentially problematic
because of the changing terminology: parents
of children with a diagnosis of the hyperactive
subtype or combined subtype of ADHD may
not have answered yes. Questions about history
of diagnosis and current medication treatment
similar to the questions that we used could be
added to large national surveys such as the Na-
tional Health Interview Survey, the National
Health and Nutrition Examination Survey, or
other community-based surveys. If the preva-
lence of ADHD diagnosis or ADHD medica-
tion treatment among elementary school chil-
dren in the United States is similar to the
estimates reported here, educators and public
health officials may have substantially underes-
timated the public health impact of ADHD.
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